Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rovalpituzumab Tesirine in Frontline Extensive Stage SCLC
NCT02819999Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Oct 2016
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of rovalpituzumab tesirine in small cell lung cancer (SCLC) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Dose Limiting Toxicities at 21 days, Treatment Emergent Adverse Events at 30 days and 2 more. Started Oct 2016; status: terminated.
02
Drugs
rovalpituzumab tesirine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02819999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819999.